Liesner RJ, et al. – Authors planned to detect the immunogenicity, efficacy, and safety of Nuwiq in previously untreated patients (PUPs) with severe haemophilia A (HA) in the ongoing NuProtect study. A cumulative incidence of 12.8% for high–titre (HT) inhibitors, was indicated. In addition, they observed convincing efficacy and tolerability in PUPs treated with Nuwiq.